Phosphoglycoprotein (P-gp) is highly expressed in the placental syncytiotrophoblast and prevents xenobiotics from entering the fetus. In tumor cells, P-gp-mediated substrate efflux is inhibited by selective serotonin reuptake inhibitors (SSRIs). However, nothing is known regarding the effects of SSRIs on P-gp function in the placenta or fetal tissues. We hypothesized that the SSRI sertraline would decrease P-gp-mediated drug efflux at the placenta and fetal blood–brain barrier (BBB)—increasing P-gp substrate transfer from the mother to the fetus and fetal brain. In contrast to our hypothesis, this study presents the novel findings that sertraline (4 hours exposure) increases placental P-gp-mediated efflux (P < .001), resulting in decreased drug transfer to the fetus. Meanwhile, sertraline decreases fetal (P < .001) and maternal (P < .05) BBB P-gp-mediated efflux, resulting in increased drug transfer into the fetal and maternal brain from the circulation. This suggests that P-gp regulation by sertraline is tissue specific. These findings have important clinical implications with respect to fetal protection during maternal drug therapy in pregnancy.
JulianoRLLingV. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162.
2.
ThiebautFTsuruoTHamadaHGottesmanMMPastanIWillinghamMC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84(21):7735–7738.
3.
CroopJMRaymondMHaberDThe three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989;9(3):1346–1350.
4.
GottesmanMMPastanI. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427.
5.
MacFarlandAAbramovichDREwenSWPearsonCK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. J Histochem. 1994;26(5):417–423.
6.
SunMKingdomJBaczykDLyeSJMatthewsSGGibbW. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27(6-7):602–609.
7.
KalabisGMKostakiAAndrewsMHPetropoulosSGibbWMatthewsSG. Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biol Reprod. 2005;73(4):591–597.
8.
MylonaPHoylandJASibleyCP. Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression. Placenta. 1999;20(5-6):493–496.
9.
IqbalMGibbWMatthewsSG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology. 2011;152(3):1067–1079.
10.
van KalkenCKGiacconeGvan der ValkPMultidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol. 1992;141(5):1063–1072.
11.
UedaKOkamuraNHiraiMHuman P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992;267(34):24248–24252.
12.
SchinkelAHSmitJJvan TellingenODisruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502.
13.
SchinkelAHWagenaarEvan DeemterLMolCABorstP. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698–1705.
14.
SmitJWHuismanMTvan TellingenOWiltshireHRSchinkelAH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104(10):1441–1447.
15.
SchinkelAHJonkerJW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29.
16.
AmbudkarSVKimchi-SarfatyCSaunaZEGottesmanMM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468–7485.
17.
WeissJDormannSMMartin-FacklamMKerpenCJKetabi-KiyanvashNHaefeliWE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305(1):197–204.
18.
PeerDDekelYMelikhovDMargalitR. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004;64(20):7562–7569.
19.
ArgovMKashiRPeerDMargalitR. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett. 2009;274(1):118–125.
20.
EvansJHeronJFrancombHOkeSGoldingJ. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323(7307):257–260.
21.
PetropoulosSKalabisGMGibbWMatthewsSG. Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone. Reprod Sci. 2007;14(4):321–328.
22.
PetropoulosSGibbWMatthewsSG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res. 2010;1357:9–18.
23.
MarkenPAMunroJS. Selecting a selective serotonin reuptake inhibitor: clinically important distinguishing features. Prim Care Companion J Clin Psychiatry. 2000;2(6):205–210.
24.
MayerUWagenaarEDorobekBBeijnenJHBorstPSchinkelAH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997;100(10):2430–2436.
25.
FennerKSTroutmanMDKempshallSDrug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173–181.
26.
BondHBakerBBoydRDArtificial perfusion of the fetal circulation of the in situ mouse placenta: methodology and validation. Placenta. 2006;27(suppl A):S69–S75.
27.
ColesLDLeeIJHassanHEEddingtonND. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. J Pharm Sci. 2009;98(8):2832–2846.
28.
SibleyCPCoanPMFerguson-SmithACPlacental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci USA. 2004;101(21):8204–8208.
29.
McClivePJSinclairAH. Rapid DNA extraction and PCR-sexing of mouse embryos. Mol Reprod Dev. 2001;60(2):225–226.
30.
PeerDMargalitR. Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006;237(2):180–187.
GreinerBEichelbaumMFritzPThe role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147–153.
33.
AchiraMTotsukaRFujimuraHKumeT. Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats. Eur J Pharm Sci. 2002;16(1-2):29–36.
34.
UhrMGrauerMTHolsboerF. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003;54(8):840–846.
35.
ShapiroABLingV. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem. 1997;250(1):130–137.
36.
SterzKMollmannLJacobsABaumertDWieseM.Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. Chem Med Chem. 2009;4(11):1897–1911.
37.
DayanGJaultJMBaubichon-CortayHBinding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry. 1997;36(49):15208–15215.
38.
TaylorJCFerryDRHigginsCFCallaghanR. The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br J Cancer. 1999;81(5):783–789.
39.
TreziseAERomanoPRGillDRThe multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. J EMBO. 1992;11(12):4291–4303.
40.
YangCPCohenDGreenbergerLMHsuSIHorwitzSB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem. 1990;265(18):10282–10288.
41.
DevaultAGrosP. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol. 1990;10(4):1652–1663.
42.
KajijiSTalbotFGrizzutiKFunctional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry. 1993;32(16):4185–4194.
43.
Tang-WaiDFKajijiSDiCapuaFde GraafDRoninsonIBGrosP. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry. 1995;34(1):32–39.
44.
De las CuevasCSanzEJ. Safety of selective serotonin reuptake inhibitors in pregnancy. Curr Drug Saf. 2006;1(1):17–24.
45.
TuccoriMTestiAAntonioliLSafety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther. 2009;31(pt 1):1426–1453.
46.
Moses-KolkoELBogenDPerelJNeonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372–2383.
47.
CasperRCFleisherBELee-AncajasJCFollow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402–408.
48.
BerlinIWarotDLegoutVGuillemantSSchollnhammerGPuechAJ. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clin Pharmacol Ther. 1998;63(4):428–436.
49.
RaapDKEvansSGarciaFDaily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther. 1999;288(1):98–106.
